Archived explainer. For the current picture see today's TXG page.
10X GENOMICS INC A (TXG) is up +11.79% in the latest session. Our newswire has captured 1 story on TXG across 1 source in the last 36 hours, with AI sentiment reading bullish (avg 63/100).
10X Genomics Inc A (TXG) shares surged 11.79% to $62.19 in the current session, driven by a recent upgrade from a Seeking Alpha analyst who highlighted a turnaround in the company's operations. The stock opened near its 52-week high and traded in a tight range, with volume remaining at zero so far. The upgrade comes amid a broader market rally that included other major names.
A Seeking Alpha analyst upgraded TXG stock to a buy, citing the company's ongoing turnaround despite its need to demonstrate consistent performance. The analyst emphasized that 10X Genomics sells instruments, consumables, and services for biological information analysis, a market in which the company is attempting to regain traction. The upgrade appears to have catalyzed investor interest, pushing the stock toward its 52-week high. Other analysts also raised price targets, with Stephens & Co. setting a $65 target, Canaccord Genuity at $60, and Piper Sandler at $47. These adjustments reflect cautious optimism about the company’s potential, even as it remains unprofitable.
TXG has a market cap of $7.2 billion but remains unprofitable, with a trailing twelve-month (TTM) net margin of -12.2% and a TTM revenue decline of 4.3%. The stock has a beta of 2.04, indicating higher volatility than the broader market. Over the last 90 days, insiders have sold shares totaling $4.2 million, with the most recent transaction on August 17, 2026. The stock printed a fresh 52-week high on August 20, 2026, and is currently trading near its session high of $62.35. The recent price action reflects improved sentiment, with a 30-day average sentiment score of 60 out of 100 and a 7-day score of 64.
The company has no upcoming earnings date listed. Investors should monitor the breadth of analyst coverage and any follow-up from the Seeking Alpha upgrade, as well as insider activity for further signals.
AI-assisted analysis composed exclusively from headlines and data on the Top Tier newswire. Public view is delayed 4 hours from real time. Not financial advice.
10x Genomics sells instruments, consumables and services used to analyze biological information. Read why TXG stock is upgraded to a buy.
More on TXG: full news and sentiment history. Sentiment scores are AI-derived research signals, not financial advice.
Earlier TXG move explainers: 2026-08-21 · 2026-08-20 · 2026-08-19